stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)

April 1998

The FDA is requiring a stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac).

Duract is the new NSAID that just came out last fall. It's approved only for SHORT-TERM use...similar to Toradol (ketorolac).

Now there are several reports of severe hepatitis and liver failure in patients taking Duract for longer than a month.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

A new "futuristic pharmacy"
Viagra (sildenafil), the first ORAL therapy for impotence
Antithrombotics possible interaction between warfarin and acetaminophen
Infectious Diseases Some patients on Crixivan or other protease inhibitor combo therapy are noticing an unusual side effect
Dermatology whether sunscreens help prevent melanoma
Dermatology possible risk of depression and suicide in patients taking Accutane (isotretinoin)
LOTS of interest in the herb, kava
St. John's wort now comes in a patch
Smoking Cessation The first nicotine INHALER
Smoking Cessation help patients and physicians choose the right smoking cessation product
Neurology & Pain stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)
Neurology & Pain dextromethorphan for pain
nutritional drinks
Thyroid Disorders possible interaction between calcium supplements and levothyroxine
Practice new Ident-A-Drug Reference